Of particular interest, survival data from both our ICI‐therapy cohort and TCGA‐LIHC cohort demonstrated that enrichment of tumor‐in‐situ HLA‐DR+CD8+T cells portended a better prognosis for HCC patients (Figure S7F,G, Supporting Information). This evidence concerns the gene CD8A and hepatocellular carcinoma.